Literature DB >> 15742455

Multicentric reticulohistiocytosis responding to tumor necrosis factor-alpha inhibition in a renal transplant patient.

Sean E Shannon1, H Ralph Schumacher, Sally Self, Alan N Brown.   

Abstract

Multicentric reticulohistiocytosis (MRH) is a rare systemic disease that characteristically produces severe erosive arthritis of the distal and proximal interphalangeal joints along with cutaneous nodules over the upper extremities and face, but it can be found in other organs. There is no known etiology, and it often remits spontaneously within 5-10 years, but can result in severe disfigurement. The diagnosis is made when histologic analysis of involved synovium or cutaneous nodules reveals characteristic histopathology. We describe a case of MRH manifesting as erosive arthritis that developed despite immunosuppressive therapy. Based on studies reporting tumor necrosis factor-a (TNF-alpha) positive cells within MRH lesions, we began treatment with TNF-alpha inhibition. Within 2 months the patient showed dramatic clinical and serologic improvement that was maintained until she stopped treatment secondary to an upper respiratory tract infection. Once treatment was restarted, the symptoms again improved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15742455

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Hand surgery for Multicentric Reticulohistiocytosis: A new avenue of treatment and review of the literature.

Authors:  Ryckie G Wade; Sachin Daivajna; Peter Chapman; Joseph G Murphy; Damodar Makkuni
Journal:  Int J Surg Case Rep       Date:  2013-05-22

Review 2.  Multicentric reticulohistiocytosis: a rare yet challenging disease.

Authors:  Arshia D Islam; Stanley M Naguwa; Gurtej S Cheema; John C Hunter; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

Review 3.  Multicentric reticulohistiocytosis: case report with response to infliximab and review of treatment options.

Authors:  Cristina C Macía-Villa; Antonio Zea-Mendoza
Journal:  Clin Rheumatol       Date:  2014-04-15       Impact factor: 2.980

Review 4.  Adalimumab in dermatology.

Authors:  Pawel Traczewski; Lidia Rudnicka
Journal:  Br J Clin Pharmacol       Date:  2008-07-11       Impact factor: 4.335

Review 5.  Tumor necrosis factor antagonists in the treatment of multicentric reticulohistiocytosis: Current clinical evidence.

Authors:  Hongjun Zhao; Chunmei Wu; Mengyun Wu; Yaou Zhou; Honglin Zhu; Yisha Li; Yunhui You; Hui Luo; Lijing Wang; Xiaoxia Zuo
Journal:  Mol Med Rep       Date:  2016-05-12       Impact factor: 2.952

Review 6.  Informed consent and biological agents in rheumatology and internal medicine.

Authors:  Gabriele Mandarelli; Florenzo Iannone; Stefano Ferracuti; Ignazio Grattagliano; Marcello Benevento; Biagio Solarino; Davide Ferorelli; Roberto Catanesi
Journal:  Eur J Clin Invest       Date:  2022-05-18       Impact factor: 5.722

7.  Multicentric reticulohistiocytosis presenting with papulonodular skin lesions and arthritis mutilans.

Authors:  Raya Saba; Shawn G Kwatra; Bishwas Upadhyay; Aibek E Mirrakhimov; Farah N Khan
Journal:  Case Rep Rheumatol       Date:  2013-03-10

Review 8.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494

Review 9.  Multicentric reticulohistiocytosis (MRH): case report with review of literature between 1991 and 2014 with in depth analysis of various treatment regimens and outcomes.

Authors:  Saad Tariq; Steven T Hugenberg; Stefanie A Hirano-Ali; Hassan Tariq
Journal:  Springerplus       Date:  2016-02-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.